Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer
Anton Safonov,Antonio Marra,Chaitanya Bandlamudi,Ben O'Leary,Bradley Wubbenhorst,Emanuela Ferraro,Enrico Moiso,Minna Lee,Julia Ah-Reum An,Mark Donoghue,Marie Will,Fresia Pareja,Emily Nizialek,Natalia Lukashchuk,Eleni Sofianopoulou,Yuan Liu,Xin Huang,Mehnaj Ahmed,Miika M Mehine,Dara Ross,Diana Mandelker,Nikolaus Schultz,Michael Berger,Maurizio Scaltriti,Jorge S Reis-Filho,Bob T Li,Ken Offit,Larry Norton,Ronglai Shen,Sohrab Shah,Kara N Maxwell,Fergus Couch,Susan M Domchek,David B Solit,Katherine L Nathanson,Mark E Robson,Nicholas C Turner,Sarat Chandarlapaty,Pedram Razavi
DOI: https://doi.org/10.1101/2024.02.05.578934
2024-08-26
Abstract:The co-occurrence of germline and somatic oncogenic alterations is frequently observed in breast cancer, but their combined biologic and clinical significance has not been evaluated. To assess the role of germline-somatic interactions on outcomes in routine practice, we developed an integrated clinicogenomic pipeline to analyze the genomes of over 4,500 patients with breast cancer. We find that germline (g) -associated tumors are enriched for loss-of-function mutations and manifest poor outcomes on standard-of-care, front-line CDK4/6 inhibitor (CDK4/6i) combinations. Amongst these tumors, g -related homologous recombination deficiency (HRD) as well as baseline LOH status promote acquisition of loss-of- function mutations under the selective pressure of CDK4/6i, causing therapy resistance. These findings suggest an alternative therapeutic strategy using sequential targeting of HRD in g associated breast cancers through PARP inhibitors CDK4/6i therapy to intercept deleterious -loss trajectories and thus suppress the emergence of CDK4/6 inhibitor resistance. More broadly, our findings demonstrate how germline-somatic driven genomic configurations shape response to systemic therapy and can be exploited therapeutically as part of biomarker-directed clinical strategies.
Genomics